Regulus Therapeutics (RGLS) Tops Q1 EPS by 3c

Regulus Therapeutics (NASDAQ: RGLS) reported Q1 EPS of ($0.42), $0.03 better than the analyst estimate of ($0.45).

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
• DHT Holdings Q2 TCE earnings estimated at $126,700 per day
• PBF Energy (PBF) PT Raised to $57 at Mizuho